Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 81
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT02590952 | A Phase I Study of Epitinib(HMPL-813) in Patients With Advanced Solid Tumors | ||
| NCT02966821 | Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma | ||
| NCT02133157 | Phase I Study of Sulfatinib(HMPL-012) in Patients With Advanced Solid Tumors | ||
| NCT02374645 | A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC | ||
| NCT02588170 | Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors | ||
| NCT01773018 | Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors | ||
| NCT04645940 | Fruquintinib Food Effect and Proton Pump Inhibitor Study | ||
| NCT04923945 | Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients | ||
| NCT02017236 | A Food Effect Phase I Study of the Volitinib in Healthy Subjects | ||
| NCT05522738 | Safety and Efficacy of Fruquintinib+FOLFIRI in RAS-mutated Metastatic Colorectal Cancer | ||
| NCT02966171 | A Dose Escalation Study to Assess the Safety and Tolerability of HMPL-453 in Patients With Advanced Solid Malignancies | ||
| NCT02252913 | A Study of Safety and Pharmacokinetics of Volitinib With Docetaxel in Patients With Advanced Gastric Cancer | ||
| NCT02691299 | A Phase III Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer | ||
| NCT03091192 | Savolitinib vs. Sunitinib in MET-driven PRCC. | ||
| NCT03684967 | Study of Fruquintinib (HMPL-013) in High Risk Patients With Advanced NSCLC | ||
| NCT02589821 | Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors | ||
| NCT03231501 | HMPL-813 in Treating Patients With Glioblastoma | ||
| NCT04372394 | A Study to Assess the Effect of a High Fat Meal on Surufatinib in Healthy Subjects | ||
| NCT03597971 | HMPL004-6599 Phase I Dose-escalating Study | ||
| NCT04716634 | Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors | ||
| NCT03627520 | A Mass Balance Study to Investigate the Absorption, Metabolism, and Excretion of [14C]Sulfatinib | ||
| NCT03483259 | To Explore the Pharmacokinetics and Relative Bioavailability of Sulfatinib Capsules in Two Different Manufacturers | ||
| NCT06437353 | Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer | ||
| NCT02314819 | A Phase III Trial Evaluating Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients （FRESCO) | ||
| NCT02415023 | A Phase Ib/2 Clinical Study of Fruquintinib Combined With Paclitaxel in the Treatment of Advanced Gastric Cancer | ||
| NCT05173142 | HMPL-453 (FGFR Inhibitor) in Combination With Chemotherapy or Anti-PD-1 Antibody in Advanced Solid Tumors | ||
| NCT05318820 | A Clinical Study to Evaluate the Pharmacokinetics and Bioequivalence of HMPL-523 Tablets Produced by Two Different Manufacturers | ||
| NCT02976116 | A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer | ||
| NCT01645215 | Phase I Study of Fruquintinib(HMPL-013) in Patients With Advanced Solid Tumors | ||
| NCT02857998 | A Study of Hutchison MediPharma Limited(HMPL)-523 in Patients With Relapsed or Refractory Mature B-cell Neoplasms | ||
| NCT02614495 | Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma | ||
| NCT03251378 | A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers | ||
| NCT05029635 | Phase III Study on HMPL-523 for Treatment of ITP | ||
| NCT03860532 | Phase I Clinical Trial in Healthy Male Volunteers | ||
| NCT02196688 | Study of Fruquintinib in Patients With Metastatic Colorectal Cancer | ||
| NCT01882764 | HMPL-004 Maintenance Treatment in Subjects With Mild to Moderate Ulcerative Colitis | ||
| NCT02320409 | A Food Effect Phase I Study of the Sulfatinib in Healthy Subjects (HMPL-012) | ||
| NCT01805791 | A Phase III Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis | ||
| NCT03223376 | A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA) | ||
| NCT04755075 | Surufatinib Hepatic Impairment Study | ||
| NCT04923932 | Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients | ||
| NCT05015621 | A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma | ||
| NCT05842525 | Fruquintinib Plus FOLFIRI in RAS-mutated Metastatic Colorectal Cancer | ||
| NCT04557397 | Fruquintinib CYP3A Inhibitor and Inducer Study | ||
| NCT05511051 | A Prospective Multi-centered Randomized Controlled Trial on Fruquintinib in Combination With HAIC in the Treatment of Liver Metastatic Colorectal Cancer After Failure of Second-line Systematic Therapy | ||
| NCT03860948 | A Pharmacokinetic and Bioequivalence Study of Savolitinib Tablets in Healthy Chinese Male Volunteers | ||
| NCT04290325 | HMPL-453 in Advanced Malignant Mesothelioma | ||
| NCT04510649 | Surufatinib DDI With a PPI and a CYP3A Inducer | ||
| NCT02503033 | A Study of HMPL-523 in Relapsed or Refractory Hematologic Malignancies | ||
| NCT03951623 | The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia Patients |
